Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

The South African Health Products Regulatory Authority (SAHPRA) has expressed concern at the increasing presence of counterfeit Glucagon-like Peptide (GLP-1) products, such as Ozempic, on the local ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...

In the U.S. Veterans Affairs Medical System, Black patients and those of Asian or Native American ancestry were less likely to receive semaglutide than white patients for diabetes or weight loss, ...

They are expected to act as a catalyst in medicine, society, the economy, and even in... fuel consumption - The astounding ...

In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...

Conditions are getting a bit more challenging for the drugmaker.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...